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cardiac operations, a novel concept first introduced by 
Angelini and colleagues 2 and carefully evaluated by Kallis 
and associates, 3 is of unusual interest. 
The authors' comments in the discussion, "the satisfac- 
tory reduction in postoperative blood loss in the aprotinin 
group prompted us to analyze the results of blood loss in 
a smaller subgroup of patients undergoing coronary artery 
bypass who continued to take aspirin until 1 week before 
the operation," are disconcerting and require an explana- 
tion. 
~i~ek and colleagues 4 have already demonstrated such 
a benefit in the recent past in a similar group of patients. 
Is there an overlap between the patients in these two 
studies? 
In the latter publication, 4 the final sentence states that 
"higher risk patients need to be investigated." In this 
article, 4 patients receiving aspirin within 7 days were 
excluded. It is this very group of 14 patients in the 
aprotinin group which received aspirin that is the crux of 
this more recent article, 1but we are not informed as to 
whether they were truly prospectively randomized on the 
basis of this preoperative characteristic. If not, then 
although the reported ifferences in blood loss are strik- 
ing, statistically speaking, the possibility of type I! error 
5 6 rises to beyond 20%. ' Hence the strict scientific merit is 
lessened. 
A new prospective randomized trial addressing patients 
expected to be at significant risk for bleeding after cardiac 
operations is required to answer whether postoperative 
aprotinin is effective in reducing blood product use after 
cardiac surgery. 
J. M. Alvarez, MD 
Consultant Cardiothoracic Surgeon 
Monash Medical Centre 
Melbourne 3168, Australia 
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Reply to the Editor: 
We thank Dr. Alvarez for his interest in our articles. 
However, We are surprised by his implications regarding 
our patient population. There is no overlap between the 
patients in these two studies. In regard to the randomiza- 
tion process, We would like to stress that patients in the 
more recent article are truly prospectively randomized 
with strict statistical criteria. 
Sertaq ~ifek, MD 
Section of Cardiovascular Surgery 
Mayo Clinic 
200 First St. 
Rochester, MN 55905 
Harun Tatar, MD 
Department of Cardiovascular Surgery 
GA TA, Gidhane School of Medicine 
Ankara, Turkey 
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Hypothermia during preconditioned ischemia- 
reperfusion attenuates the myocardial protection 
of preconditioning 
To the Editor." 
Perrault and colleagues 1 are to be congratulated on 
their elegant and sophisticated study in exploring ischemic 
preconditioning in cardiac surgery. However, the authors 
conclude that "preconditioning does not enhance car- 
dioplegic protection and might even be deleterious." This 
potentially important conclusion was thrown into doubt by 
a number of significant limitations by Dr. Steven F. 
Bolling, in his discussion of the article: (1) Is the model 
actually a model of ischemic preconditioning? (2) Did 
preconditioning occur? (3) Why were right atrial biopsy 
specimens used? (4) Why were a few unimportant indices 
used, instead of the sensitive indices such as protein 
kinase C isoenzymes, in explaining the occurrence of 
preconditioning? 
We are also part of a group that studies preconditioning 
both in animal experiments and in clinical trials in cardiac 
surgery.2, 3 Many factors can interfere with the induction 
of preconditioning. Recently, we conducted research on 
the effects of hypothermia during preconditioned isch- 
emia-reperfusion the myocardial protection of precon- 
ditioning in isolated perfused rat hearts (Table I). Male 
Sprague-Dawley rat hearts were used in the model of 
modified Langendorff perfusion. Preconditioning was elic- 
ited by a single 5-minute period of ischemia and a 
10-minute period of reperfusion. After preconditioning, 
all hearts were arrested by infusion of 4 ° C St. Thomas' 
Hospital cardioplegic solution, 5 ml per dose, every 30 
minutes for 3 hours and then reperfused by 37 ° C Krebs- 
Henseleit buffer solution for 45 minutes. The results 
indicated that hypothermic preconditioning attenuates 
the myocardial protection of preconditioning, asshown in 
Table I. We therefore doubt that the hearts in the 
experimental group in Perrault's tudy were really precon- 
ditioned. For the purpose of exploring the effectiveness of 
preconditioning protocol in cardiac operations, ST-seg- 
ment depression was used as a predictor of precondi- 
tioned ischemia in our studies (unpublished ata). In 
addition, many details throughout the operation can dis- 
turb the results of preconditioning from an opposite view 
in cardiac surgery. These factors mainly include unstable 
anesthesia, cardiopulmonary b pass, body temperature, 
